Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01449279 · ClinicalTrials.gov registry record · Phase 2
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01449279: Completed Phase 2 study, sponsored by Stanford University.
NCT01449279 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01449279, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.
Primary Outcome
Serious adverse events (SAEs) defined as untoward medical occurrence that at any dose: results in death, is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires in subject hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect,
Interventions
- DRUG Ipilimumab
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-12-01 |
| Phase | Phase 2 |
What the finished NCT01449279 record still lists
NCT01449279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01449279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01449279 about?
NCT01449279 is a clinical study titled "Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy". To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.
What is the current status of trial NCT01449279?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2011-10. Estimated completion is 2016-12-01.
What interventions are being tested in trial NCT01449279?
The interventions under investigation include: Ipilimumab (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01449279?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01449279's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia